These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21689507)

  • 1. [Tapentadol is a new, strongly efficative analgeticum with dual effect mechanisms].
    Staahl C; Drewes AM; Jensen NH
    Ugeskr Laeger; 2011 Jun; 173(25):1796-9. PubMed ID: 21689507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy.
    Niesters M; Proto PL; Aarts L; Sarton EY; Drewes AM; Dahan A
    Br J Anaesth; 2014 Jul; 113(1):148-56. PubMed ID: 24713310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery .
    Stegmann JU; Weber H; Steup A; Okamoto A; Upmalis D; Daniels S
    Curr Med Res Opin; 2008 Nov; 24(11):3185-96. PubMed ID: 18851776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tapentadol, but not morphine, selectively inhibits disease-related thermal hyperalgesia in a mouse model of diabetic neuropathic pain.
    Christoph T; De Vry J; Tzschentke TM
    Neurosci Lett; 2010 Feb; 470(2):91-4. PubMed ID: 20026182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor.
    Hartrick CT; Rozek RJ
    CNS Drugs; 2011 May; 25(5):359-70. PubMed ID: 21476608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antinociceptive and antihyperalgesic effect of tapentadol is partially retained in OPRM1 (μ-opioid receptor) knockout mice.
    Kögel B; De Vry J; Tzschentke TM; Christoph T
    Neurosci Lett; 2011 Mar; 491(2):104-7. PubMed ID: 21232580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial.
    Schwartz S; Etropolski M; Shapiro DY; Okamoto A; Lange R; Haeussler J; Rauschkolb C
    Curr Med Res Opin; 2011 Jan; 27(1):151-62. PubMed ID: 21162697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule.
    Tzschentke TM; Jahnel U; Kogel B; Christoph T; Englberger W; De Vry J; Schiene K; Okamoto A; Upmalis D; Weber H; Lange C; Stegmann JU; Kleinert R
    Drugs Today (Barc); 2009 Jul; 45(7):483-96. PubMed ID: 19834626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution?
    Candiotti KA; Gitlin MC
    Curr Med Res Opin; 2010 Jul; 26(7):1677-84. PubMed ID: 20465361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride.
    Etropolski M; Kelly K; Okamoto A; Rauschkolb C
    Adv Ther; 2011 May; 28(5):401-17. PubMed ID: 21494892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tapentadol-ER for the treatment of diabetic peripheral neuropathy.
    Games G; Hutchison A
    Consult Pharm; 2013 Oct; 28(10):672-5. PubMed ID: 24129223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-relevant outcomes and health-related quality of life in patients with chronic, severe, noncancer pain treated with tapentadol prolonged release-Using criteria of health technology assessment.
    Hofmann JF; Lal A; Steffens M; Boettger R
    J Opioid Manag; 2016; 12(5):323-331. PubMed ID: 27844472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immediate-release tapentadol or oxycodone for treatment of acute postoperative pain after elective arthroscopic shoulder surgery: a randomized, phase IIIb study.
    Vorsanger GJ; Klopfer AM; Xiang J; Benson CJ; Moskovitz BL; Rosenthal NR
    J Opioid Manag; 2013; 9(4):281-90. PubMed ID: 24353022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized controlled trial of the combined monoaminergic and opioid investigational compound GRT9906 in painful polyneuropathy.
    Sindrup SH; Konder R; Lehmann R; Meier T; Winkel M; Ashworth J; Baron R; Jensen TS
    Eur J Pain; 2012 Jul; 16(6):849-59. PubMed ID: 22337471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised, placebo-controlled trial comparing the effects of tapentadol and oxycodone on gastrointestinal and colonic transit in healthy humans.
    Jeong ID; Camilleri M; Shin A; Iturrino J; Boldingh A; Busciglio I; Burton D; Ryks M; Rhoten D; Zinsmeister AR
    Aliment Pharmacol Ther; 2012 May; 35(9):1088-96. PubMed ID: 22348605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical value of tapentadol extended-release in painful diabetic peripheral neuropathy.
    Desai B; Freeman E; Huang E; Hung A; Knapp E; Breunig IM; McPherson ML; Shaya FT
    Expert Rev Clin Pharmacol; 2014 Mar; 7(2):203-9. PubMed ID: 24524594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain.
    Daniels S; Casson E; Stegmann JU; Oh C; Okamoto A; Rauschkolb C; Upmalis D
    Curr Med Res Opin; 2009 Jun; 25(6):1551-61. PubMed ID: 19445652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of tapentadol ER for managing moderate to severe chronic pain.
    Afilalo M; Morlion B
    Pain Physician; 2013 Jan; 16(1):27-40. PubMed ID: 23340531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain.
    Frampton JE
    Drugs; 2010 Sep; 70(13):1719-43. PubMed ID: 20731478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.
    Hartrick C; Van Hove I; Stegmann JU; Oh C; Upmalis D
    Clin Ther; 2009 Feb; 31(2):260-71. PubMed ID: 19302899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.